# A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting

> **NCT07700966** · — · RECRUITING · sponsor: **Abeona Therapeutics, Inc** · enrollment: 250 (estimated)

## Conditions studied

- Recessive Dystrophic Epidermolysis Bullosa

## Interventions

- **COMBINATION_PRODUCT:** Prademagene Zamikeracel

## Key facts

- **NCT ID:** NCT07700966
- **Lead sponsor:** Abeona Therapeutics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-25
- **Primary completion:** 2045-04
- **Final completion:** 2045-04
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2026-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07700966

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07700966, "A Long-Term Safety Follow-up Registry for Patients Who Received Treatment With Prademagene Zamikeracel for Recessive Dystrophic Epidermolysis Bullosa (RDEB) in the Post-Marketing Setting". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07700966. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*